# A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

> **NCT04571164** · PHASE3 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 294 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** LY03003(Rotigotine,extended-release microspheres)
- **DRUG:** Placebo,extended-release microspheres

## Key facts

- **NCT ID:** NCT04571164
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-11
- **Primary completion:** 2022-03-17
- **Final completion:** 2022-09-27
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571164, "A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04571164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*